Sandbox:MGS: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(32 intermediate revisions by 2 users not shown)
Line 1: Line 1:
===Pathogenesis===
===Discovery===
Waldenström Macroglobulinemia is uncontrolled clonal proliferation of terminally differentiated B lymphocytes, which are normally involved in humoral immunity.<ref name="HP">Waldenström's macroglobulinemia. Wikipedia (2015)https://en.wikipedia.org/wiki/Waldenström%27s_macroglobulinemia#Pathophysiology Accessed on November 6, 2015</ref>
*The oldest evidence of cancer is discovered in the Egyptian literature and dates back to about 3000 BC. The textbook is called the 'Edwin Smith Papyrus' and describes 8 cases of tumors of the breast that were removed by [[cauterization]] with a tool called the fire drill. The writing says about the disease, “There is no treatment.<ref>{{cite web
In Waldenström Macroglobulinemia, peripheral B lymphocyte are stimulated to undergo somatic hypermutation of the immunoglobulin heavy chain gene in the germinal center, without class switching.
  | title = The History of Cancer
 
  | work = [[American Cancer Society]]
===Genetics===
  | date = 2002-03-25
====Whole genome sequencing====
  | url = http://www.cancer.org/docroot/CRI/content/CRI_2_6x_the_history_of_cancer_72.asp?sitearea=CRI
*Development of Waldenström Macroglobulinemia is the result of multiple gene mutations.<ref name="HP">Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenström macroglobulinemia. UpToDate (2015)http://www.uptodate.com/contents/epidemiology-pathogenesis-clinical-manifestations-and-diagnosis-of-waldenstrom-macroglobulinemia?source=see_link Accessed on November 9, 2015</ref>
  | accessdate = 2006-10-09 }}</ref>  
*Genes involved in pathogenesis of Waldenström Macroglobulinemia are:
===Landmark Events in the Development of Treatment Strategies===
:*MYD88 L265P in chromosome 3p22.2
*In 1761, Giovanni Morgagni of Padua became the first to perform an autopsy to relate the illness to the pathology.
:*CXCR4
* The Scottish surgeon John Hunter (1728-1793) suggested that cancer could be removed if tumor had not invaded nearby tissue and was 'moveable'.
::*MYD88: has a role in toll-like receptor and interleukin-1 receptor signaling causing activation of transcription factors of the NF-kB family. Thus, activating point mutation of MYD88 augments growth and survival of both normal and neoplastic B cells by preventing apoptosis. MYD88 also has role in BTK signaling which also helps in B cell growth and survival. Point mutation of MYD88 leads to leucine (L) to proline (P) substitution in codon 265 (L265P) of MYD88 and produces constantly overactive protein causing proliferation of malignant cells that should normally undergo apoptosis.
*In 1700s, John Hunter, the Scottish surgeon suggested that tumors grow from lymph constantly thrown out by the blood.
 
*In 19th century, Rudolf Virchow became the first to correlate the illness to microscopic pathology.
<ref name="HP">Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenström macroglobulinemia. UpToDate (2015)http://www.uptodate.com/contents/epidemiology-pathogenesis-clinical-manifestations-and-diagnosis-of-waldenstrom-macroglobulinemia?source=see_link Accessed on November 9, 2015</ref><ref name="Genetics">Waldenström macroglobulinemia. Genetics Home Reference (2015)http://ghr.nlm.nih.gov/condition/waldenstrom-macroglobulinemia Accessed on November 9, 2015</ref>
*Zacutus Lusitani (1575-1642) and Nicholas Tulp (1593-1674), 2 doctors in Holland, publicized their work in 1649 and 1652 respectively that concluded that breast cancer was contagious based on their observation of the tumor in the members of the same household.
::* Patients with Waldenström Macroglobulinemia with co-existing mutation of MYD88 & CXCR4 are more likely to have hyperviscosity syndrome and bone marrow involvement.
*In the 1990s, BRCA1 and BRCA2 genes were associated with development of breast cancer for first time.  
 
*In 1713, Bernardino Ramazzini, an Italian doctor, reported the relatively high incidence of breast cancer in nuns. This observation made it a clear association between breast cancer and role of hormones.
===Associated Conditions===
*In late 1960s, modern mammography methods were developed.
 
*In 1976, mammography became officially recommended by the American cancer society.
===Pathology===
*In the last decade of the 19th century, William Stewart Halsted, professor of surgery at Johns Hopkins University, came up with the radical mastectomy procedure.
====Gross pathology====
*In 1719, Lorenz Heister, a German surgeon wrote about his ideas for mastectomy and lumpectomy in his book, Chirurgie.
====Microscopic pathology====
*In 1896, Thomas Beatson, a graduate from the University of Edinburgh, described the relationship between oophorectomy and breast cancer. This study laid down the foundation of the hormonal therapy of the breast cancer.
====Immunohistochemistry====
*In the 1970s, modern clinical trials demonstrated that less extensive surgery is equally effective for most women with breast cancer.
Malignant cells in Waldenström Macroglobulinemia express IgM surface immunoglobulin and lack IgD.
*During the final decades of the 20th century, technices were developed to minimizing the amount of normal tissue removed along with the tumor.
Lymphocytic component: expresses pan B cell antigens
*In late 1990s, first therapeutic monoclonal antibodies, trastuzumab (Herceptin) was approved for breast cancer.
Plasma cell component: expresses CD138
Majority of malignant cells express:
*Adhesion molecules including:
:*L-selectin
:*ICAM-1
:*CD44
:*CD11c
*Lymphocyte function associated antigen 1 (LFA-1)
 
References:
{{Reflist}}

Latest revision as of 21:50, 23 January 2016

Discovery

  • The oldest evidence of cancer is discovered in the Egyptian literature and dates back to about 3000 BC. The textbook is called the 'Edwin Smith Papyrus' and describes 8 cases of tumors of the breast that were removed by cauterization with a tool called the fire drill. The writing says about the disease, “There is no treatment.”[1]

Landmark Events in the Development of Treatment Strategies

  • In 1761, Giovanni Morgagni of Padua became the first to perform an autopsy to relate the illness to the pathology.
  • The Scottish surgeon John Hunter (1728-1793) suggested that cancer could be removed if tumor had not invaded nearby tissue and was 'moveable'.
  • In 1700s, John Hunter, the Scottish surgeon suggested that tumors grow from lymph constantly thrown out by the blood.
  • In 19th century, Rudolf Virchow became the first to correlate the illness to microscopic pathology.
  • Zacutus Lusitani (1575-1642) and Nicholas Tulp (1593-1674), 2 doctors in Holland, publicized their work in 1649 and 1652 respectively that concluded that breast cancer was contagious based on their observation of the tumor in the members of the same household.
  • In the 1990s, BRCA1 and BRCA2 genes were associated with development of breast cancer for first time.
  • In 1713, Bernardino Ramazzini, an Italian doctor, reported the relatively high incidence of breast cancer in nuns. This observation made it a clear association between breast cancer and role of hormones.
  • In late 1960s, modern mammography methods were developed.
  • In 1976, mammography became officially recommended by the American cancer society.
  • In the last decade of the 19th century, William Stewart Halsted, professor of surgery at Johns Hopkins University, came up with the radical mastectomy procedure.
  • In 1719, Lorenz Heister, a German surgeon wrote about his ideas for mastectomy and lumpectomy in his book, Chirurgie.
  • In 1896, Thomas Beatson, a graduate from the University of Edinburgh, described the relationship between oophorectomy and breast cancer. This study laid down the foundation of the hormonal therapy of the breast cancer.
  • In the 1970s, modern clinical trials demonstrated that less extensive surgery is equally effective for most women with breast cancer.
  • During the final decades of the 20th century, technices were developed to minimizing the amount of normal tissue removed along with the tumor.
  • In late 1990s, first therapeutic monoclonal antibodies, trastuzumab (Herceptin) was approved for breast cancer.
  1. "The History of Cancer". American Cancer Society. 2002-03-25. Retrieved 2006-10-09.